Randomized study to compare Paclitaxel/Topotecan vs. Cisplatin/Topotecan in patients with recurrent cervical cancer - AGO-Cervix-1 study

被引：0
|
作者：
Thiel, F. C. [1 ]
Hilpert, F. [2 ]
Rein, D. [3 ]
Liebrich, C. [4 ]
Fasching, P. A. [5 ]
Beckmann, M. W. [5 ]
机构：
[1] Univ Frauenklin Erlangen, Erlangen, Germany
[2] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
[3] Univ Frauenklin, Dusseldorf, Germany
[4] Klinikum Stadt Wolfsburg, Frauenklin, Wolfsburg, Germany
[5] Univ Klinikums Erlangen, Frauenklin, Erlangen, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2008年 / 68卷
关键词：
cervical cancer; paclitaxel; recurrent; topotecan;
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Phase I study of topotecan continuous infusion and weekly cisplatin with radiation therapy for locally advanced/recurrent cervical cancer.
    Padilla, LA
    Mitchell, SK
    Carson, LF
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 486S - 486S
  • [22] Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study
    Tewari, Krishnansu S.
    Sill, Michael W.
    Birrer, Michael J.
    Penson, Richard T.
    Huang, Helen
    Moore, David H.
    Ramondetta, Lois M.
    Landrum, Lisa M.
    Oaknin, Ana
    Reid, Thomas J.
    Leitao, Mario M.
    Michael, Helen E.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2023, 171 : 141 - 150
  • [23] Phase II Study of Topotecan with Cisplatin in Japanese Patients with Small Cell Lung Cancer
    Hosomi, Yukio
    Shibuya, Masahiko
    Niho, Seiji
    Ichinose, Yukito
    Kiura, Katsuyuki
    Sakai, Hiroshi
    Takeda, Koji
    Kudo, Shinzo
    Eguchi, Kenji
    Matsui, Kaoru
    Masuda, Noriyuki
    Ando, Masahiro
    Watanabe, Koshiro
    ANTICANCER RESEARCH, 2011, 31 (10) : 3449 - 3456
  • [24] Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study
    Ghamande, SA
    Piver, MS
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 72 (03) : 162 - 166
  • [25] A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer
    Lu, C
    Komaki, R
    Lee, JS
    Shin, DM
    Palmer, JL
    Coldman, BJ
    Pisters, KM
    Kurie, JM
    Fossella, FV
    Glisson, BS
    CLINICAL CANCER RESEARCH, 2003, 9 (06) : 2085 - 2091
  • [26] A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
    Manci, N.
    Marchetti, C.
    Di Tucci, C.
    Giorgini, M.
    Esposito, F.
    Palaia, I.
    Musella, A.
    Perniola, G.
    Carrone, A.
    Panici, P. Benedetti
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 285 - 290
  • [27] Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer
    Levy, T
    Inbar, M
    Menczer, J
    Grisaru, D
    Glezerman, M
    Safra, T
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 686 - 690
  • [28] Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study
    Stathopoulos, GP
    Rigatos, SK
    Christodoulou, C
    Malamos, NA
    Deliyiannis, F
    Stathopoulos, JG
    Skarlos, DV
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (03) : 259 - 264
  • [29] Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study
    George P. Stathopoulos
    Sotiris K. Rigatos
    Christos Christodoulou
    Nikos A. Malamos
    Filippos Deliyiannis
    John G. Stathopoulos
    Dimosthenis V. Skarlos
    Cancer Chemotherapy and Pharmacology, 2004, 54 : 259 - 264
  • [30] Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study
    Schoemaker, NE
    Herbert, VMM
    de Jong, LA
    van Waardenburg, RCAM
    Pluim, D
    Huinink, WWT
    Beijnen, JH
    Schellens, JHM
    ANTI-CANCER DRUGS, 2002, 13 (01) : 87 - 91
12345